pharma · No medical condition. · Breast cancer
George Institute for
The George Institute
George Institute is a pharma organization headquartered in KOLKATA, IN. Primary therapeutic focus areas include No medical condition., Breast cancer, Metastatic colorectal cancer, Prostate Cancer, advanced/metastatic HER
Sydney, NSW 2042, AU HQ
1999 Founded
841 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Sydney, NSW 2042, AU
- Founded
- 1999
- Employees
- 841
- Programs
- 406
- Drugs
- 522
- Patents
- 0
BDTX-4933-101
Phase 2 · small molecule · Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mutations
BDTX-4933-101 for Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mutations is a Phase 2 program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).
Internal code BDTX-4933-101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- The George Institute
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mutations
- Status
- active
- Trials
- 1